Assessment of Norwegian physicians’ knowledge, experience and attitudes towards medical cannabis

References

• Ablin, J. N., Elkayam, O., & Fitzcharles, M. A. (2016). Attitudes of Israeli rheumatologists to the use of medical cannabis as therapy for rheumatic disorders. Rambam Maimonides Medical Journal, 7(2), e0012. https://doi.org/10.5041/RMMJ.10239
   PubMed Web of Science ®Google Scholar
• Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515–521. https://doi.org/10.1212/01.wnl.0000253187.66183.9c
   PubMed Web of Science ®Google Scholar
• Adler, J. N., & Colbert, J. A. (2013). Clinical decisions. Medicinal use of marijuana–polling results. The New England Journal of Medicine, 368(22), e30. https://doi.org/10.1056/NEJMclde1305159
   PubMed Web of Science ®Google Scholar
• Ananth, P., Ma, C., Al-Sayegh, H., Kroon, L., Klein, V., Wharton, C., Hallez, E., Braun, I., Michelson, K., Rosenberg, A. R., London, W., & Wolfe, J. (2018). Provider perspectives on use of medical marijuana in children with cancer. Pediatrics, 141(1), e20170559. https://doi.org/10.1542/peds.2017-0559
   PubMed Web of Science ®Google Scholar
• Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford, England), 45(1), 50–52. https://doi.org/10.1093/rheumatology/kei183
   PubMed Web of Science ®Google Scholar
• Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. The Journal of Pain, 17(6), 739–744. https://doi.org/10.1016/j.jpain.2016.03.002
   PubMed Web of Science ®Google Scholar
• Brooks, E., Gundersen, D. C., Flynn, E., Brooks-Russell, A., & Bull, S. (2017). The clinical implications of legalizing marijuana: Are physician and non-physician providers prepared. Addictive Behaviors, 72, 1–7. https://doi.org/10.1016/j.addbeh.2017.03.007
   PubMed Web of Science ®Google Scholar
• Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. The American Journal of Psychiatry, 161(11), 1967–1977. https://doi.org/10.1176/appi.ajp.161.11.1967
   PubMed Web of Science ®Google Scholar
• Bushlin, I., Rozenfeld, R., & Devi, L. A. (2010). Cannabinoid-opioid interactions during neuropathic pain and analgesia. Current Opinion in Pharmacology, 10(1), 80–86. https://doi.org/10.1016/j.coph.2009.09.009
   PubMed Web of Science ®Google Scholar
• Carlini, B. H., Garrett, S. B., & Carter, G. T. (2017). Medicinal cannabis. American Journal of Hospice and Palliative Medicine^®, 34(1), 85–91. https://doi.org/10.1177/1049909115604669
   PubMed Web of Science ®Google Scholar
• Charuvastra, A., Friedmann, P. D., & Stein, M. D. (2005). Physician attitudes regarding the prescription of medical marijuana. Journal of Addictive Diseases, 24(3), 87–93. https://doi.org/10.1300/J069v24n03_07
   PubMed Web of Science ®Google Scholar
• Clark, A. J., Ware, M. A., Yazer, E., Murray, T. J., & Lynch, M. E. (2004). Patterns of cannabis use among patients with multiple sclerosis. Neurology, 62(11), 2098–2100. https://doi.org/10.1212/01.WNL.0000127707.07621.72
   PubMed Web of Science ®Google Scholar
• Consroe, P., Musty, R., Rein, J., Tillery, W., & Pertwee, R. (1997). The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology, 38(1), 44–48. https://doi.org/10.1159/000112901
   PubMed Web of Science ®Google Scholar
• Crowley, D., Collins, C., Delargy, I., Laird, E., & Van Hout, M. C. (2017). Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey. Harm Reduction Journal, 14(1), 4. https://doi.org/10.1186/s12954-016-0129-7
   PubMed Web of Science ®Google Scholar
• de Lago, E., & Fernández-Ruiz, J. (2007). Cannabinoids and neuroprotection in motor-related disorders. CNS & Neurological Disorders Drug Targets, 6(6), 377–387. https://doi.org/10.2174/187152707783399210
   PubMedGoogle Scholar
• Doblin, R. E., & Kleiman, M. A. (1991). Marijuana as antiemetic medicine: a survey of oncologists’ experiences and attitudes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 9(7), 1314–1319. https://doi.org/10.1200/JCO.1991.9.7.1314
   PubMed Web of Science ®Google Scholar
• Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018). The endogenous cannabinoid system: A budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 43(1), 52–79. https://doi.org/10.1038/npp.2017.204
   PubMed Web of Science ®Google Scholar
• Ebert, T., Zolotov, Y., Eliav, S., Ginzburg, O., Shapira, I., & Magnezi, R. (2015). Assessment of Israeli physicians’ knowledge, experience and attitudes towards medical cannabis: A pilot study. The Israel Medical Association Journal: IMAJ, 17(7), 437–441.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. (2016). Cannabis Policy status and recent developments. Retrieved March 4, 2018, from http://www.emcdda.europa.eu/topics/cannabis-policy#section1
   Google Scholar
• Fitzcharles, M.-A., Ste-Marie, P. A., Clauw, D. J., Jamal, S., Karsh, J., LeClercq, S., McDougall, J. J., Shir, Y., Shojania, K., & Walsh, Z. (2014). Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskeletal Disorders, 15, 258. https://doi.org/10.1186/1471-2474-15-258
   PubMed Web of Science ®Google Scholar
• Hall, W. (2015). What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction (Abingdon, England), 110(1), 19–35. https://doi.org/10.1111/add.12703
   PubMed Web of Science ®Google Scholar
• Hall, W., & Weier, M. (2015). Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clinical Pharmacology and Therapeutics, 97(6), 607–615. https://doi.org/10.1002/cpt.110
   PubMed Web of Science ®Google Scholar
• Kavia, R. B., De Ridder, D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 16(11), 1349–1359. https://doi.org/10.1177/1352458510378020
   PubMed Web of Science ®Google Scholar
• Killestein, J., Hoogervorst, E. L. J., Reif, M., Kalkers, N. F., Van Loenen, A. C., Staats, P. G. M., Gorter, R. W., Uitdehaag, B. M. J., & Polman, C. H. (2002). Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 58(9), 1404–1407. https://doi.org/10.1212/wnl.58.9.1404
   PubMed Web of Science ®Google Scholar
• Kondrad, E., & Reid, A. (2013). Colorado family physicians’ attitudes toward medical marijuana. Journal of the American Board of Family Medicine: JABFM, 26(1), 52–60. https://doi.org/10.3122/jabfm.2013.01.120089
   PubMed Web of Science ®Google Scholar
• Kristensen, Ø., & Mlodozeniec, A. (2017). The debate about cannabis. Tidsskrift for Den Norske Laegeforening: Tidsskrift for Praktisk Medicin, ny Raekke, 137(5), 344–344. []. https://doi.org/10.4045/tidsskr.17.0067
   PubMed Web of Science ®Google Scholar
• Kweskin, S. (2013). The dope on medical cannabis: Results of a survey of psychiatrists. Psychiatric Times, 30 (7), 11–17.
   Google Scholar
• Michalec, B., Rapp, L., & Whittle, T. (2015). Assessing phsyicians’ perspectives and knowledge of medical marijuana and the Delaware medical marijuana act. The Journal of Global Drug and Policy and Practice, 9(3), 1–24.
   Google Scholar
• Norwegian Medicines Agency (NMA). (2018). Behandling med medisinsk cannabis innenfor dagens regelverk. Retrieved March 23, 2018, from https://legemiddelverket.no/bivirkninger-og-sikkerhet/rad-til-helsepersonell/behandling-med-medisinsk-cannabis-innenfor-dagens- regelverk
   Google Scholar
• Nussbaum, A. M., Boyer, J. A., & Kondrad, E. C. (2011). “But my doctor recommended pot”: medical marijuana and the patient-physician relationship. Journal of General Internal Medicine, 26(11), 1364–1367. https://doi.org/10.1007/s11606-011-1840-4
   PubMed Web of Science ®Google Scholar
• Pisanti, S., & Bifulco, M. (2017). Modern history of medical cannabis: From widespread use to prohibitionism and back. Trends in Pharmacological Sciences, 38(3), 195–198. https://doi.org/10.1016/j.tips.2016.12.002
   PubMed Web of Science ®Google Scholar
• Ringard, Å., Sagan, A., Sperre Saunes, I., & Lindahl, A. K. (2013). Norway: health system review. Health Systems in Transition, 15(8), 1–162.
   PubMedGoogle Scholar
• Robson, P. (2001). Therapeutic aspects of cannabis and cannabinoids. The British Journal of Psychiatry: The Journal of Mental Science, 178, 107–115. https://doi.org/10.1192/bjp.178.2.107
   PubMed Web of Science ®Google Scholar
• Rubens, M. (2014). Political and medical views on medical marijuana and its future. Social Work in Public Health, 29(2), 121–131. https://doi.org/10.1080/19371918.2013.821351
   PubMed Web of Science ®Google Scholar
• Sarvet, A. L., Wall, M. M., Fink, D. S., Greene, E., Le, A., Boustead, A. E., Pacula, R. L., Keyes, K. M., Cerdá, M., Galea, S., & Hasin, D. S. (2018). Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis. Addiction (Addiction), 113(6), 1003–1016. https://doi.org/10.1111/add.14136
   PubMed Web of Science ®Google Scholar
• Schlossarek, S., Kempkensteffen, J., Reimer, J., & Verthein, U. (2016). Psychosocial determinants of cannabis dependence: A systematic review of the literature. European Addiction Research, 22(3), 131–144. https://doi.org/10.1159/000441777
   PubMed Web of Science ®Google Scholar
• Statistics Norway. (2020). Andelen kvinner i medisinen: Noen utviklingstrekk baser på Legeforeningens statistikk. Retrieved April 5, 2020, from https://www.legeforeningen.no/contentassets/0bdafe0d9fe0431bb968fa006ffef34d/kvinneandel-og-antallet-kvinnelige-leger-1930-2020.pdf
   Google Scholar
• Stortinget. (2017). Representantforslag fra stortingsrepresentant Una Aina Basthol om en rusreform for å sikre skadeforebygging og individuell helsehjelp til rusavhengige. Retrieved April 9, 2018, from https://www.stortinget.no/nn/Saker-og-ublikasjonar/publikasjonar/Representantframlegg/2017-2018/dok8-201718-029s/
   Google Scholar
• Sznitman, S. R., & Zolotov, Y. (2015). Cannabis for therapeutic purposes and public health and safety: A systematic and critical review. The International Journal on Drug Policy, 26(1), 20–29. https://doi.org/10.1016/j.drugpo.2014.09.005
   PubMed Web of Science ®Google Scholar
• Teigen, I. A., Serkland, T. T., Pahr, T., & Berg, J. A. (2019). Should more patients be offered treatment with cannabinoids. Tidsskrift for Den Norske Laegeforening: tidsskrift for Praktisk Medicin, ny Raekke, 139(13)
   Web of Science ®Google Scholar
• Troutt, W. D., & DiDonato, M. D. (2015). Medical cannabis in Arizona: Patient characteristics, perceptions, and impressions of medical cannabis legalization. Journal of Psychoactive Drugs, 47(4), 259–266. https://doi.org/10.1080/02791072.2015.1074766
   PubMed Web of Science ®Google Scholar
• Tynkkynen, L. K., Alexandersen, N., Kaarbøe, O., Anell, A., Lehto, J., & Vrangbaek, K. (2018). Development of voluntary private health insurance in Nordic countries – An exploratory study on country-specific contextual factors. Health Policy (Netherlands), 122(5), 485–492. https://doi.org/10.1016/j.healthpol.2018.03.008
   PubMed Web of Science ®Google Scholar
• Uritsky, T. J., McPherson, M. L., & Pradel, F. (2011). Assessment of hospice health professionals’ knowledge, views, and experience with medical marijuana. Journal of Palliative Medicine, 14(12), 1291–1295. https://doi.org/10.1089/jpm.2011.0113
   PubMed Web of Science ®Google Scholar
• Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G. J., & Collet, J.-P. (2010). Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Canadian Medical Association Journal, 182(14), E694–E701. https://doi.org/10.1503/cmaj.091414
   PubMed Web of Science ®Google Scholar
• Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456–2473. https://doi.org/10.1001/jama.2015.6358
   PubMed Web of Science ®Google Scholar
• Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008). A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. The Journal of Pain, 9(6), 506–521. https://doi.org/10.1016/j.jpain.2007.12.010
   PubMed Web of Science ®Google Scholar
• Ziemianski, D., Capler, R., Tekanoff, R., Lacasse, A., Luconi, F., & Ware, M. A. (2015). Cannabis in medicine: A national educational needs assessment among Canadian physicians. BMC Medical Education, 15, 52. https://doi.org/10.1186/s12909-015-0335-0
   PubMed Web of Science ®Google Scholar